Beijing Aosaikang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of active pharmaceutical ingredients and formulations in China. It also offers digestive health products, which include pump inhibitors suitable for various digestive tract-related diseases, such as peptic ulcers, reflux esophagitis, and upper gastrointestinal bleeding; and anti-tumor products, including the treatment of non-small cell lung cancer, colorectal cancer, and breast cancer, encompassing targeted therapy, chemotherapy, endocrine therapy, and adjuvant medications. In addition, the company provides anti-infective products comprising a product defense line against bacterial and invasive fungal infections; and the chronic disease field focusing on chronic diseases requiring long-term management consisting of diabetes, osteoarthritis, thrombocytopenia, and iron overload. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 1996 and is based in Nanjing, China.
Research context
Beijing Aosaikang Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Beijing Aosaikang Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 8.0% below its 200 day moving average.
From a valuation standpoint, the stock is 26.9% cheaper than other stocks from the Industrials sector with a price to sales ratio of 3.7.
Beijing Aosaikang Pharmaceutical Co., Ltd's total revenue rose by 23.3% to $1B since the same quarter in the previous year.
Its net income has increased by 29.0% to $251M since the same quarter in the previous year.
Finally, its free cash flow grew by 600.0% to $192M since the same quarter in the previous year.
Based on the above factors, Beijing Aosaikang Pharmaceutical Co., Ltd gets an overall score of 4/5.